Background: Therapy-related serious adverse events (SAEs) are important causes of morbidity in patients with GPA or MPA. Long-term safety data of rituximab in GPA/MPA are limited. Objectives: To characterize safety events in an observational registry of patients with GPA/MPA initiating rituximab. Methods: This interim analysis of RaVeR, an ongoing open-label real-world study of adult patients with GPA or MPA initiating rituximab (dose/frequency determined by investigator), was conducted when 50% of patient-years (PY) were collected (July 2015). Safety events included serious infections (SI), infusionrelated reactions (IRR), serious cardiac events, malignancies, and other serious events. Crude incidence rates (IR) and 95% CI were calculated. Trial registration number: NCT01613599 Results: 97 patients (291 PY) received rituximab, of whom 70% received rituximab retreatment. Median follow-up was 2.4 years. Overall, 91% of patients were ANCApositive and 78% had GPA. 17 patients (17.5%) had a history of plasmapheresis or dialysis; 20 (20.6%) were receiving rituximab plus cyclophosphamide at baseline. 33 patients had 71 SAEs (32.4/100 PYs [95% CI: 25.32-40.89]). 11 patients had 20 SIs (9.13/100 PYs [95% CI: 5.58-14.10]). 9 patients (9.3%) experienced 13 serious cardiovascular (CV) events (5.93/100 PYs [95% CI: 3.16-10.15]), 12 of which were reported as unrelated to rituximab. Of the 13 CV events, 9 were atrial arrhythmias and most patients had associated renal or CV disease history. There were no serious IRRs or SAEs within 24 hours of rituximab infusion. There were 6 deaths (2.74/100 PYs [95% CI: 1.01-5.96]); causes of death included septic shock, interstitial lung disease, congestive heart failure, cardio-respiratory arrest and 2 deaths of unknown etiology. The severe disease flare rate was 5.94/100 PYs (95% CI: 3.16-10.15). Among patients who received rituximab retreatment, the IRs of SAEs (26.1/100 PYs) and SIs (7.29/100 PYs) were not increased compared with the overall cohort.
